Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Gerresheimer AG
  6. News
  7. Summary
    GXI   DE000A0LD6E6

GERRESHEIMER AG

(GXI)
  Report
Real-time Estimate Tradegate  -  01:22 2022-10-04 pm EDT
52.98 EUR   +4.18%
05:58aGERRESHEIMER AG : Deutsche Bank keeps its Buy rating
MD
04:23aGERRESHEIMER AG : Credit Suisse gives a Buy rating
MD
09/21GERRESHEIMER AG : JP Morgan remains Neutral
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gerresheimer Invests Up to $94 Million in US Production Facility

08/09/2022 | 01:00am EDT

Gerresheimer AG announced investments to rapidly expand its manufacturing, supply and logistics capability for glass vials in the U.S. The project will be supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) with contracting support from the Department of Defense (DOD). It will expand Gerresheimer's capacity by new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging. BARDA has agreed to provide up to approximately 66 million US-Dollar to Gerresheimer AG for this project.

The investment is part of Gerresheimer's global expansion plan and follows its formula G strategy process. Under the agreement, Gerresheimer will increase its annual production capacity in Morganton, NC with interchangeable Type 1 vials (glass borosilicate and/or aluminosilicate) and Gx Elite Glass Vials capability. BARDA's financing, with contracting support from the DOD'sJoint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the Army Contracting Command (ACC), will strengthen the capabilities in the U.S. to respond to current and future public health emergencies.

The vials can be used in vaccination campaigns against infectious diseases, such as COVID-19 and others. This expansion of the facility will further strengthen Gerresheimer's leading market position in best-in-class elite vials. As part of the project, the existing facility in North Carolina will be enlarged by the installation of new vial forming lines and a new warehouse.

As the investment will lead to an increase in the number of people employed, new offices will also be part of the expansion plan.


© S&P Capital IQ 2022
All news about GERRESHEIMER AG
05:58aGERRESHEIMER AG : Deutsche Bank keeps its Buy rating
MD
04:23aGERRESHEIMER AG : Credit Suisse gives a Buy rating
MD
09/21GERRESHEIMER AG : JP Morgan remains Neutral
MD
09/19Gerresheimer : Andrea Abt
PU
09/19Dd : Gerresheimer AG : Notification and public disclosure of transactions by persons
EQ
09/07Stevanato, Gerresheimer Develop Ready-to-Use Vial Solution
MT
09/07Gerresheimer AG and Stevanato Group Announces Collaboration on the Development of an In..
CI
09/07Gerresheimer Ag : Gerresheimer AG and Stevanato Group announce Collaboration on the Develo..
EQ
08/19GERRESHEIMER AG : JP Morgan sticks Neutral
MD
08/17Gerresheimer Ag : Gerresheimer and Zollner enter into a strategic partnership for electron..
EQ
More news
Analyst Recommendations on GERRESHEIMER AG
More recommendations
Financials
Sales 2022 1 727 M 1 699 M 1 699 M
Net income 2022 106 M 104 M 104 M
Net Debt 2022 1 079 M 1 062 M 1 062 M
P/E ratio 2022 15,0x
Yield 2022 2,59%
Capitalization 1 597 M 1 571 M 1 571 M
EV / Sales 2022 1,55x
EV / Sales 2023 1,42x
Nbr of Employees 10 803
Free-Float 100%
Chart GERRESHEIMER AG
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 50,85 €
Average target price 86,56 €
Spread / Average Target 70,2%
EPS Revisions
Managers and Directors
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
GERRESHEIMER AG-39.96%1 571
ABBOTT LABORATORIES-29.29%174 281
MEDTRONIC PLC-20.06%109 921
BECTON, DICKINSON AND COMPANY-6.10%65 817
HOYA CORPORATION-18.82%34 410
DEXCOM, INC.-36.69%33 362